Plus: TMRW Vault® receives CE Mark as Class IIa medical device, and halving ART costs could more than double births.
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals, a transaction that includes Crinetics’ drug Palsonify for acromegaly and a late-stage therapy for congenital adrenal hyperplasia, impacting companies developing treatments for hormonal disorders. This acquisition, coupled with TMRW Vault® receiving CE Mark as a Class IIa medical device, and research demonstrating that halving patient out-of-pocket costs for ART could increase births by 2.67-fold, highlights the financial and regulatory considerations for femtech operators. Five takes inside, plus a quick-hits roundup.
VIA STAT News
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals, which values the company at roughly $85 per share. The acquisition includes Crinetics’ drug Palsonify for acromegaly and a late-stage therapy for congenital adrenal hyperplasia. This acquisition impacts companies developing treatments for hormonal disorders.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire – Health
On July 6, Reprotech announced TMRW Vault® received CE Mark as a Class IIa medical device under Regulation (EU) 2017/745. This CE Mark supports the medical device's commercialization in the European Union and other markets. Femtech operators can anticipate increased availability of this fertility technology in European markets.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire Health
Halving patient out-of-pocket costs for assisted reproductive technology (ART) led to a 2.67-fold increase in births. The 42nd Annual Meeting of the European Society for Human Reproduction and Embryology (ESHRE) presented these findings. This data suggests financial accessibility directly impacts ART utilization and birth rates for fertility-focused femtech operators and insurers.
Read the full story →
— The Luteal Editorial Team
VIA PR Newswire Health
Halving patient out-of-pocket costs for fertility treatment could increase births achieved through assisted reproductive technology (ART) by 2.67-fold. The 42nd Annual Meeting of the European Society presented this finding. This suggests that reducing financial barriers can significantly expand access to fertility services for patients.
Read the full story →
— The Luteal Editorial Team